Announcements Trials
Browse Landscape

Phase

Phase 2 3

Status

Recruiting 4Completed 4Not yet recruiting 3Unknown 2

Sponsor Class

OTHER 3

Study Type

Interventional 3

Sponsor

Cancer Type

Gastrointestinal 3

Conditions

Carcinoma, Hepatocellular 16Carcinoma, Renal Cell 3Biliary Tract Neoplasms 3Uterine Cervical Neoplasms 2Stomach Neoplasms 2Liver Neoplasms 2Cholangiocarcinoma 2Advanced Endometrial Cancer 2Thyroid Neoplasms 1Solid Tumors 1Recurrence 1Neoplasm Metastasis 1Hepatitis B 1Esophageal Squamous Cell Carcinoma 1Diabetes Mellitus, Insulin-Dependent, 12 1Clear-cell metastatic renal cell carcinoma 1Cirrhosis, Familial, with Pulmonary Hypertension 1Breast Neoplasms 1Bone Neoplasms 1BTC 1Advanced Triple Negative Breast Cancer 1Advanced Non-squamous Non-small-cell Lung Cancer 1Advanced Hepatocellular Carcinoma (HCC) 1Adenocarcinoma 1

Interventions

Gemcitabine 7Cisplatin 6Oxaliplatin 5Fluorouracil 4lenvatinib 3envafolimab 3S 1 (combination) 3Capecitabine 3toripalimab 2pembrolizumab 2Leucovorin 2Irinotecan 2Folfox protocol 2tislelizumab 1tegafur-gimeracil-oteracil 1surufatinib 1pertuzumab 1mitazalimab 1durvalumab 1disitamab vedotin 1camrelizumab 1anlotinib 1Simvastatin 1Self Expandable Metallic Stents 1Bevacizumab 1Albumin-Bound Paclitaxel 1Actigraphy 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Not yet recruiting × Biliary Tract Neoplasms × lenvatinib × Clear all
NCT07159217 2025-09-08

Disitamab Vedotin Plus Lenvatinib and PD-1 Inhibitors for Treating HER2-positive Advanced Biliary Tract Cancer

Peking Union Medical College Hospital

Phase 2 Not yet recruiting
65 enrolled
Gastrointestinal

Biliary Tract Neoplasms

NCT06919848 2025-04-09

Oncolytic Virus H101 Combined With Lenvatinib Plus Toripalimab Compared With FOLFOX in Patients With Advanced Biliary Tract Cancer (OPTIONS-06)

Fudan University

Phase 2 Not yet recruiting
74 enrolled
Gastrointestinal

Biliary Tract Neoplasms

NCT06389500 2024-04-29

HAIC+Adebrelimab+Lenvatinib for Conversion Treatment of Potentially Resectable, Locally Advanced Biliary Tract Cancer

Harbin Medical University

Phase 2 Not yet recruiting
30 enrolled
Gastrointestinal

Biliary Tract Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡